API's
Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients
Rabeprazole Sodium EC Pellets and Domperidone SR Pellets are formulated as a fixed-dose combination designed for complementary therapeutic action in the management of acid-related gastrointestinal disorders, including GERD, functional dyspepsia, and nausea associated with delayed gastric emptying.
This dual-pellet system ensures sequential drug release:
1. Domperidone SR Pellets are released gradually to enhance gastric motility and reduce symptoms like bloating and nausea.
2. Rabeprazole EC Pellets release in the intestine (protected by enteric coating), where they inhibit gastric acid secretion effectively.
| Component | Function |
|---|---|
| Rabeprazole Sodium | Active Pharmaceutical Ingredient (API) |
| Sugar Spheres / MCC Pellets | Inert Core Material |
| Hydroxypropyl Methylcellulose (HPMC) | Seal coating & binder |
| Methacrylic Acid Copolymers (Eudragit L100 / S100) | Enteric coating polymer |
| Polyvinyl Acetate Phthalate (PVAP) | Acid-resistant enteric polymer |
| Triethyl Citrate | Plasticizer for flexibility in enteric film |
| Talc | Anti-adherent |
| Colloidal Silicon Dioxide | Glidant and anti-caking agent |
| Isopropyl Alcohol / Purified Water | Solvent system for coating (evaporated) |
| Domperidone | Active Pharmaceutical Ingredient (API) |
| Microcrystalline Cellulose (MCC) | Pellet core and filler |
| Hydroxypropyl Methylcellulose (HPMC K100M / K15M) | Sustained-release matrix former |
| Ethyl Cellulose (N-50 / RS) | Rate-controlling polymer for SR coating |
| Povidone K30 | Binder |
| Talc | Anti-adherent |
| Colloidal Silicon Dioxide | Glidant |
| Isopropyl Alcohol / Purified Water | Solvent system for layering and coating |
Salius Pharma’s Rabeprazole Sodium EC + Domperidone SR Pellets are manufactured in USFDA-approved, WHO-GMP, and ISO-certified facilities, ensuring superior quality and regulatory compliance. This dual-release formulation combines enteric-coated Rabeprazole for targeted intestinal delivery with sustained-release Domperidone to provide prolonged antiemetic action. Our pellets are customizable in strength and particle size, and are designed for excellent flowability and compressibility, making them ideal for use in capsules, tablets, or sachets. With comprehensive regulatory documentation (including DMF, COA, MSDS) and a strong track record of global exports to regions like Africa, LATAM, MENA, and Southeast Asia, Salius Pharma is a trusted partner for integrated GI combination therapies.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Rabeprazole Sodium EC Pellets + Domperidone SR Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
These pellets combine enteric-coated Rabeprazole to inhibit stomach acid with sustained-release Domperidone to improve gastrointestinal motility, providing effective relief from acid reflux, heartburn, and dyspepsia.
Yes. They can be used in capsule filling, sachets, or tablet compression, offering flexibility in formulation and ensuring consistent drug release.
Absolutely. Customization options include drug load ratios, pellet size, coating materials, and release profiles to meet specific therapeutic and regulatory requirements.